TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM

IMPORTANCE OF TDI EXPERIENCES IN EUROPE FOR UNODC

• EU WORK ON HARMONIZATION OF DATA COLLECTION SYSTEMS PROVIDES IMPORTANT GUIDANCE ON HOW TO WORK AT GLOBAL LEVEL.

• TREATMENT DATA ARE IN MANY COUNTRIES THE ONLY DATA COLLECTED AND IMPROVING THEM IS AN IMPORTANT ELEMENT OF BUILDING NATIONAL INFORMATION SYSTEM.

REPORTING ON DRUG DEMAND REDUCTION• Developing an information set to measure achievement in respect of the targets

detailed in the Political Declaration and the Demand Reduction Declaration• Goals for 2003: establishment of legal measures and programmes (reviewed

during the Ministerial Segment of the Commission on Narcotic Drugs in April 2003)

• Goals for 2008: to significantly reduce demand for illicit drugs.

ACTION PLAN ON DEMAND REDUCTION

Under the Action Plan UNODC has been given 3 specific tasks:–To facilitate sharing of good practice strategies and programmes–To provide assistance in developing DDR strategies in line with the Guiding principles of drug demand reduction –To provide assistance for the establishment of national data collection systems.

GUIDING PRINCIPLES OF UNDCP DATA COLLECTION STRATEGY

• Sensitivity to different information resources

• Based on agreed standards of good practice

• Comparability with other information sets

BIENNIAL REPORTS QUESTIONNAIRE (BRQ)on Demand Reduction Activities• Mandated follow-up instrument of the UNGASS process

• To enable Member States to report on the progress

achieved in meeting the UNGASS objectives for 2003 and

2008

• To monitor structures, methods of working, target

population, extent and coverage of programmes,

difficulties encountered

BIENNIAL REPORTS QUESTIONNAIRE (BRQ)on Demand Reduction Activities

• Extent of coverage (low /medium or high) and programme execution (gender sensitive and evaluated in the areas of treatment and rehabilitation:

• detoxification• substitution treatment (therapy) excluding short-term

detoxification • non-pharmacological treatment • social reintegration

ANNUAL REPORTS QUESTIONNAIRE (ARQ)on Drug Abuse

• To review the progress made in meeting the

challenges set out in the Political Declaration

adopted by the General Assembly

• To monitor and increase global understanding of

the extent and nature of drug abuse

ANNUAL REPORTS QUESTIONNAIRE (ARQ)

Quantitative estimates and expert opinions on:

• prevalence of drug abuse among general and youth population

• prevalence of drug abuse among the school (youth) population

• injecting drug abuse

• severe drug abuse

• new developments in prevalence and patterns of drug abuse

• drug-related morbidity (HIV, HBV, HCV)

• Drug-related mortality

• drug treatment

• data collection capacity

ANNUAL REPORTS QUESTIONNAIRE (ARQ)

• Annually distributed to all Member States

• Annual Reports Questionnaire, 2001:103

submissions, response rate 54 %

• Electronic completion and submission made

possible

ANNUAL REPORTS QUESTIONNAIRE (ARQ) TREATMENT DEMAND

• Summary Expert Opinions

– Have people received treatment yes/no by drugs

– Ranking drugs as primary cause of receiving treatment

– Trends in the past in number of people receiving treatment (large/some increase/decrease or stable)

ANNUAL REPORTS QUESTIONNAIRE (ARQ) TREATMENT DEMAND

• Quantitative Estimates

– Estimated number of people receiving treatment– Percentage of people receiving treatment for first time ever– Percentage of females– Mean age– Percentage of drug injectors– Definition of “people treated for drug problems”

No. of people receiving treatment for cannabis type in Asia

71

15

5

2

1698

217

1

0 200 400 600 800 1000 1200 1400 1600 1800

Indonesia

Korea (Republic of)

Macau

Mongolia

Philippines

Saudi Arabia

Tajikistan

Asia

No. of people receiving treatment for cannabis type in Europe

12953030

2392301

600728

1245250865

3443256184336

3489

0 2000 4000 6000 8000 10000 12000 14000

CroatiaFranceGreece

HungaryIcelandIreland

ItalyLatv ia

LiechtensteinLux embourgNetherlands

PolandSlov akiaSw eden

United Kingdom

Euro

pe

No. of people receiving treatment for cannabis type in the Americas

214

11

7

20

116

88

0 50 100 150 200 250

Argentina

Dominican Republic

Grenada

Haiti

Saint Vincent and the Grenadines

Trinidad Tobago

Amer

icas

Percentage of people receiving treatment for the first ever time among people in treament for cannabis type

9684

81

8071

6966

6156

4023

191414

9

84

0 10 20 30 40 50 60 70 80 90 100

SeychellesIndonesia

Greece

LatviaSlovakia

Netherlands

Ireland

Saudi ArabiaFrance

LiechtensteinHaiti

Saint Vincent and the Grenadines

Mauritius

MongoliaDominican Republic

Hungary

Grenada

Estimated mean age of people in treatment for cannabis type

Seychelles 23Dominican Republic 25Saint Kitts and Nevis 25Saint Vincent and the Grenadines 29Korea (Republic of) 31Saudi Arabia 28Croatia 16France 26Greece 21Ireland 22Liechtenstein 22Netherlands 28Slovakia 20Turkey 28

Estimated percentage of females among people in treatment for cannabis type

Mauritius 2Seychelles 8Saint Vincent and the Grenadines 5Trinidad Tobago 8Indonesia 4Macau 1Croatia 4France 18Greece 11Hungary 4Ireland 18Latvia 20Netherlands 19Poland 2Slovakia 18Turkey 8United Kingdom 18

Global Assessment Programme on Drug Abuse (GAP)

The Global Assessment Programme (GAP) on Drug Abuse has facilitated an understanding of and improved information on the global drug situation.

Lisbon consensus January 2000 agreement on a set of core Indicators•Prevalence and incidende general population•Prevalence and incidence youth population•High-risk drug abuse•Drug-related morbidity•Drug-related mortality

Global Assessment Programme on Drug Abuse (GAP)

At the national level the GAP has:

•conducted information, need and resource analyses to produce strategic action plans

•Supported the establishment of data collection focal points and expert networks

•Provided training and resources to meet key information needs

Global Assessment Programme (GAP)Through its regional activities:• GAP has supported regional information systems• Encouraged networking among countries • Provided opportunities for trainingAt the global level:• Dissemination of methodological developments and best

practices (toolkit with modules on information systems, school surveys, estimation techniques, data management and analysis)

• Improved reporting standards• Increased the quality and coverage of the global information base

Global Assessment Programme (GAP) next steps• Technical support to regional sub-programmes and

national epidemiological units • Further development and harmonization of indicators and

data collection methodologies• Regional network development and exchange of

information, experience and survey results among national epidemiological units in the region;

• Promotion of the use of existing training packages (“methodological toolkit”) developed under the GAP and provision of technical assistance for regional training;

Global Assessment Programme (GAP) next steps• Development of training packages and organization

of regional training programmes on: • ARQ data management and interpretation to support policy planning; • Qualitative research and focused assessment studies;• Ethical issues and principles for drug abuse epidemiology;• Treatment reporting (possible cooperation with EMCDDA and other

agencies);• Monitoring of injecting drug abuse and associated HIV-related factors

• Technical assistance to national focal points in collection of national and regional data on drug abuse